Voriconazole-Induced Phototoxicity Masquerading as Chronic Graft-versus-Host Disease of the Skin in Allogeneic Hematopoietic Cell Transplant Recipients

Biology of Blood and Marrow Transplantation

Volumn 15, Issue 3, 2009, Pages 370-376

  Patel, Asha R ^a   Turner, Maria L ^a   Baird, Kristin ^a   Gea Banacloche, Juan ^b   Mitchell, Sandra ^a   Pavletic, Steven Z ^b   Wise, Barbara ^a   Cowen, Edward W ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Graft versus host disease, Voriconazole, Phototoxicity, Fungal infection

Indexed keywords

ITRACONAZOLE; POSACONAZOLE; PREDNISONE; RITUXIMAB; VORICONAZOLE;

ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLISTER; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; DIFFERENTIAL DIAGNOSIS; DRUG DOSE INCREASE; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERYTHEMA; FATALITY; FEMALE; GRAFT RECIPIENT; HUMAN; LICHEN PLANUS; LIVER DISEASE; LUNG ASPERGILLOSIS; LUNG NODULE; LUPUS LIKE SYNDROME; MACULOPAPULAR RASH; MALE; NEOPLASM; PHOTOTOXICITY; PORPHYRIA CUTANEA TARDA; PSEUDOPORPHYRIA; PUNCH BIOPSY; RETROSPECTIVE STUDY; SCLERODERMA; SKIN BIOPSY; SKIN DEFECT; SKIN EDEMA; SKIN NECROSIS; VITILIGO;

ADOLESCENT; ADULT; ANTIFUNGAL AGENTS; CHILD; DERMATITIS, PHOTOTOXIC; DIAGNOSIS, DIFFERENTIAL; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MYCOSES; PYRIMIDINES; RETROSPECTIVE STUDIES; TRIAZOLES;

EID: 59349104365     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.12.491     Document Type: Article

References (36)

1. Marr K.A., Carter R.A., Boeckh M., Martin P., and Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 100 (2002) 4358-4366
2. Upton A., Kirby K.A., Carpenter P., Boeckh M., and Marr K.A. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 44 (2007) 531-540
3. Herbrecht R., Denning D.W., Patterson T.F., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347 (2002) 408-415
4. Wingard J.R., Carter S.L., Walsh T.J., et al. Results of a randomized, double-blind trial of fluconazole (FLU) vs. voriconazole (VORI) for the prevention of invasive fungal infections (IFI) in 600 allogeneic blood and marrow transplant (BMT) patients. ASH Annu Meet Abstr 110 (2007) 163
5. Vfend (Voriconazole, Oral and Intravenous Formulations), NDA 21-267, Briefing Document for FDA Antiviral Drugs Advisory Committee Meeting, 4 October 2001. Pfizer Inc. [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3792b2_01_Pfizer.pdf [Accessed 2007 October 18].
6. Stein K.R., and Scheinfeld N.S. Drug-induced photoallergic and phototoxic reactions. Expert Opin Drug Saf 6 (2007) 431-443
7. Toback A.C., and Anders J.E. Phototoxicity from systemic agents. Dermatol Clin 4 (1986) 223-230
8. Denning D.W., and Griffiths C.E. Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole. Clin Exp Dermatol 26 (2001) 648-653
9. Walsh T.J., Lutsar I., Driscoll T., et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 21 (2002) 240-248
10. Cortez K.J., Walsh T.J., and Bennett J.E. Successful treatment of coccidioidal meningitis with voriconazole. Clin Infect Dis 36 (2003) 1619-1622
11. Vandecasteele S.J., Van Wijngaerden E., and Peetermans W.E. Two cases of severe phototoxic reactions related to long-term outpatient treatment with voriconazole. Eur J Clin Microbiol Infect Dis 23 (2004) 656-657
12. Rubenstein M., Levy M.L., and Metry D. Voriconazole-induced retinoid-like photosensitivity in children. Pediatr Dermatol 21 (2004) 675-678
13. Racette A.J., Roenigk Jr. H.H., Hansen R., Mendelson D., and Park A. Photoaging and phototoxicity from long-term voriconazole treatment in a 15-year-old girl. J Am Acad Dermatol 52 5 Suppl. 1 (2005) S81-S85
14. Hilliard T., Edwards S., Buchdahl R., et al. Voriconazole therapy in children with cystic fibrosis. J Cyst Fibros 4 (2005) 215-220
15. Auffret N., Janssen F., Chevalier P., Guillemain R., Amrein C., and Le Beller C. Voriconazole photosensitivity: 7 cases [in French]. Ann Dermatol Venereol 133 (2006) 330-332
16. Serra Soler G., Delgado Sánchez O., Esteban Marcos E., Martínez-López I., and Femenías Sureda M. Voriconazole-associated phototoxicity [in Spanish]. Farm Hosp 30 (2006) 386-387
17. McCarthy K.L., Playford E.G., Looke D.F., and Whitby M. Severe photosensitivity causing multifocal squamous cell carcinomas secondary to prolonged voriconazole therapy. Clin Infect Dis 44 (2007) e55-e56
18. Dolan C.K., Hall M.A., Blazes D.L., and Norwood C.W. Pseudoporphyria as a result of voriconazole use: a case report. Int J Dermatol 43 (2004) 768-771
19. Sharp M.T., and Horn T.D. Pseudoporphyria induced by Voriconazole. J Am Acad Dermatol 53 (2005) 341-345
20. Tolland J.P., McKeown P.P., and Corbett J.R. Voriconazole-induced pseudoporphyria. Photodermatol Photoimmunol Photomed 23 (2007) 29-31
21. Kwong W.T., and Hsu S. Pseudoporphyria associated with voriconazole. J Drugs Dermatol 6 (2007) 1042-1044
22. Weedon D. The lichenoid reaction pattern ("interface dermatitis"). In: Weedon D. (Ed). Skin Pathology. 2nd ed (2002), Churchill Livingstone, New York 46
23. Weedon D. Reactions to physical agents. In: Weedon D. (Ed). Skin Pathology. 2nd ed (2002), Churchill Livingstone, New York 600
24. Hood A.F., and Farmer E.R. Interface dermatitis. In: Farmer E.R., and Hood A.F. (Eds). Pathology of the Skin. 2nd ed (2000), McGraw-Hill, New York 204
25. Nghiem P. The "drug vs graft-vs-host disease" conundrum gets tougher, but there is an answer: the challenge to dermatologists. Arch Dermatol 137 (2001) 75-76
26. Ullmann A.J., Lipton J.H., Vesole D.H., et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 356 (2007) 335-347
27. Walsh T.J., Raad I., Patterson T.F., et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 44 (2007) 2-12
28. Boucher H.W., Groll A.H., Chiou C.C., and Walsh T.J. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs 64 (2004) 1997-2020
29. Segal B.H., Almyroudis N.G., Battiwalla M., et al. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. Clin Infect Dis 44 (2007) 402-409
30. Couriel D., Carpenter P.A., Cutler C., et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant 12 (2006) 375-396
31. Kitajima T., and Imamura S. Graft-versus-host reaction enhanced by ultraviolet radiation. Arch Dermatol Res 285 (1993) 499-501
32. Ibia E.O., Schwartz R.H., and Widermann B.L. Antibiotic rashes in children: a survey in a private practice setting. Arch Dermatol 136 (2000) 849-854
33. van der Linden P.D., van der Lei J., Vlug A.E., and Stricker B.H. Skin reactions to antibacterial agents in general practice. J Clin Epidemiol 51 (1998) 703-708
34. Svensson C.K., Cowen E.W., and Gaspari A.A. Cutaneous drug reactions. Pharmacol Rev 53 (2001) 357-379
35. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 11 (2005) 945-956
36. Roujeau J.C., and Stern R.S. Severe adverse cutaneous reactions to drugs. N Engl J Med 331 (1994) 1272-1285